Thomas John (Tom John)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 22

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Nature communications

British journal of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massuti, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip Font, Pei-Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Mirosław Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali A Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, null null
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Lavinia Tan, Chris Brown, Antony Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni Newnham, Kenneth O'Byrne, Sagun Parakh, Victoria Bray, Kevin Jasas, Sonia Yip, Stephen Q Wong, Sarah Ftouni, Jerick Guinto, Sushma Chandrashekar, Stephen Clarke, Nick Pavlakis, Martin R Stockler, Sarah-Jane Dawson, Benjamin J Solomon
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature communications 15 (1) (2024)
Lavinia Tan, Chris Brown, Antony Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni Newnham, Kenneth O'Byrne, Sagun Parakh, Victoria Bray, Kevin Jasas, Sonia Yip, Stephen Q Wong, Sarah Ftouni, Jerick Guinto, Sushma Chandrashekar, Stephen Clarke, Nick Pavlakis, Martin R Stockler, Sarah-Jane Dawson, Benjamin J Solomon
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature communications 15 (1) (2024)
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massuti, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip Font, Pei-Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Mirosław Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali A Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, null null
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Lavinia Tan, Chris Brown, Antony Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni Newnham, Kenneth O'Byrne, Sagun Parakh, Victoria Bray, Kevin Jasas, Sonia Yip, Stephen Q Wong, Sarah Ftouni, Jerick Guinto, Sushma Chandrashekar, Stephen Clarke, Nick Pavlakis, Martin R Stockler, Sarah-Jane Dawson, Benjamin J Solomon
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature communications 15 (1) (2024)
Lara Edbrooke, Catherine L Granger, Jillian J Francis, Thomas John, Nasreen Kaadan, Emma Halloran, Bronwen A Connolly, Linda Denehy
Rehabilitation outcomes for people with lung cancer (UNITE): protocol for the development of a core outcome set. BMJ open respiratory research 10 (1) (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Helena Alexandra Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip Font, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis G Paz-Ares, Benjamin Besse, Paolo Bironzo, Dong Wan Kim, Melissa Lynne Johnson, Yi-Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D Patel, Egbert F Smit, Karen L Reckamp, Qian Dong, Pomy Shrestha, Pang-Dian Fan, Parul Patel, Andrea Sporchia, David W Sternberg, Dalila Sellami, Pasi A Janne
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh R Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna C Bulusu, Gianluca Laus, Barbara Collins, J Carl Barrett, Ryan J Hartmaier, Vassiliki A Papadimitrakopoulou
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications 14 (1) (2023)
John F Markham, Andrew P Fellowes, Thomas Green, Jose Luis Leal, Roxane Legaie, Darren Cullerne, Tessa Morris, Thomas John, Ben Solomon, Stephen B Fox
Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. British journal of cancer 128 (6) (2022)
Margarita Majem Tarruella, Jonathan Wade Goldman, Thomas John, Christian Grohe, Konstantin Laktionov, Sang-We Kim, Terufumi Kato, Huu Vinh Vu, Shun Lu, Shanqing Li, Kye Young Lee, Charuwan Akewanlop, Chong-Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A Shepherd, Shinji Atagi, Lingmin Zeng, Dakshayini Kulkarni, Nenad Medic, Masahiro Tsuboi, Roy S Herbst, Yi-Long Wu
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (11) (2022)
John F Markham, Andrew P Fellowes, Thomas Green, Jose Luis Leal, Roxane Legaie, Darren Cullerne, Tessa Morris, Thomas John, Ben Solomon, Stephen B Fox
Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. British journal of cancer 128 (6) (2022)
John F Markham, Andrew P Fellowes, Thomas Green, Jose Luis Leal, Roxane Legaie, Darren Cullerne, Tessa Morris, Thomas John, Ben Solomon, Stephen B Fox
Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. British journal of cancer (2022)
John F Markham, Andrew P Fellowes, Thomas Green, Jose Luis Leal, Roxane Legaie, Darren Cullerne, Tessa Morris, Thomas John, Ben Solomon, Stephen B Fox
Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. British journal of cancer 128 (6) (2022)
John F Markham, Andrew P Fellowes, Thomas Green, Jose Luis Leal, Roxane Legaie, Darren Cullerne, Tessa Morris, Thomas John, Ben Solomon, Stephen B Fox
Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. British journal of cancer 128 (6) (2022)
John F Markham, Andrew P Fellowes, Thomas Green, Jose Luis Leal, Roxane Legaie, Darren Cullerne, Tessa Morris, Thomas John, Ben Solomon, Stephen B Fox
Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. British journal of cancer 128 (6) (2022)
Rachel G Woodford, Deborah Di-Xin Zhou, Sarah Sally J Lord, Ian C Marschner, Wendy Anne Cooper, Craig R Lewis, Thomas John, James Chih-Hsin Yang, Chee Khoon Lee
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future oncology (London, England) 18 (14) (2022)
George D Demetri, Filippo De Braud, Alexander E Drilon, Salvatore Siena, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R Wilson, Christian Rolfo
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (7) (2022)
Krithika Murali, Tanya M Dwarte, Mehrdad Nikfarjam, Katherine M Tucker, Rhys B Vaughan, Marios Efthymiou, Allison Collins, Allan D Spigelman, Lucinda Salmon, Amber L Johns, David B Williams, Martin B Delatycki, Thomas John, Alina Stoita
Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. Hereditary cancer in clinical practice 19 (1) (2021)
Mark G Anderson, Hugh D Falls, Michael J Mitten, Anatol Oleksijew, Kedar S Vaidya, Erwin R Boghaert, Wenqing Gao, Joann P Palma, Diana Cao, Puey-Ling Chia, Thomas John, Hui Kong Gan, Andrew M Scott, Edward B Reilly
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate. Molecular cancer therapeutics 19 (10) (2020)